Mostly Markets
Subscribe
Stocks/Health Care/Biotechnology

BiogenBIIB

Biotechnology · Cambridge, Massachusetts · In the S&P 500
Solid business
$253.62+1.59%After hours: $253.62 (0.00%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 71.5% over 1 year
Biogen over 1 yearDaily close, $, to 30 Oct 2026
$150$200Nov2026MarMayJulSep$253.62$150$200NovMarJul$253.62
Source: Nasdaq daily closes
Market value$37.49B
Price to earnings108.6x
Forward P/E20.5x
Dividend yield–
Year to date+44.1%
One year+71.5%
Next earningsNot scheduled
SectorHealth Care
52-week range (closes)
$149.33$253.84

Quality and valuation

How Biogen compares with other health care stocks. A description, not a recommendation.

Biogen and 7 biotechnology peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: about averageValuation: in line with its sector

An average business among health care companies, priced about in line with them.

Biogen trades at 20.5 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew slower than the sector median: +2.3% vs +7.8%
  • Keeps more of each sale (gross margin): 74.0% vs 65.3%
  • Turns more of its sales into cash: 20.1% vs 15.9%
  • Keeps less of its revenue as profit (net margin): 3.4% vs 9.7%
BIIB trades at 20.5x forward earnings, above the sector medianForward p/e, Biotechnology peers
REGN14.3xGILD19.4xABBV19.6xAMGN19.8xBIIB20.5xVRTX29.3xINCY61.0xSector median 19.1xREGN14.3xGILD19.4xABBV19.6xAMGN19.8xBIIB20.5xVRTX29.3xINCY61.0xSector median 19.1x
Source: CNBC quotes; Mostly Markets
At 108.4x earnings, BIIB is pricier than its average since Oct 2024Price over the last 12 months of reported (GAAP) diluted EPS
P/EUsual range (±1 s.d.)
50x100xAverage 19.3x20252026108.4x50xAverage 19.3x20252026108.4x
Source: Nasdaq prices; SEC filings

Financials

From Biogen's SEC filings, through the quarter ending 30 Sep 2026. Hover or tap a bar for its value.

Revenue grew 10.6% from a year earlierQuarterly revenue, $bn, latest Q3 ’26
$0bn$1bn$2bnQ4 ’24Q2 ’25Q4 ’25$2.8bnQ3 ’26$0bn$1bn$2bnQ4 ’24Q2 ’25Q4 ’25$2.8bnQ3 ’26
Source: SEC filings
Growth sped up to +10.6% last quarterRevenue growth, year on year, %
−5%0%5%10%Q4 ’24Q2 ’25Q4 ’2510.6%Q3 ’260%10%Q4 ’24Q2 ’25Q4 ’2510.6%Q3 ’26
Source: SEC filings
Free cash flow was $2.1 billion over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $bn
$0.0bn$0.5bn$1.0bnQ4 ’24Q2 ’25Q4 ’25$0.6bnQ3 ’26$0.0bn$0.5bn$1.0bnQ4 ’24Q2 ’25Q4 ’25$0.6bnQ3 ’26
Source: SEC filings
Diluted EPS was $-0.14 last quarterQuarterly diluted earnings per share, $
$0$2$4Q4 ’24Q2 ’25Q4 ’25−$0.14Q3 ’26$0$2$4Q4 ’24Q2 ’25Q4 ’25−$0.14Q3 ’26
Source: SEC filings
Last 12 monthsBIIBSector median
Revenue growth+2.3%+7.8%
Gross margin74.0%65.3%
Free cash flow margin20.1%15.9%
Price to earnings108.6x30.2x

Stories on Biogen

We haven't written about Biogen yet. Follow it, and its first story will show under My stocks on the front page.

Similar companies

Biotechnology, by market value.

CompanyPriceTodayYTDValue
ABBVAbbVie$294.89+1.41%+29.1%$521B
AMGNAmgen$466.01+1.15%+42.4%$252B
GILDGilead Sciences$170.68+3.06%+39.1%$212B
VRTXVertex Pharmaceuticals$558.88+3.50%+23.3%$142B
REGNRegeneron Pharmaceuticals$927.89+13.33%+20.2%$95.53B
MRNAModerna$221.72−0.47%+651.8%$88.52B
INCYIncyte$120.39+3.07%+21.9%$24.40B